Breaking News Instant updates and real-time market news.

AAOI

Applied Optoelectronics

$58.84

-2.6 (-4.23%)

, FNSR

Finisar

$22.28

0.48 (2.20%)

17:54
10/12/17
10/12
17:54
10/12/17
17:54

Applied Optoelectronics collapses after Q3 view, peers dragged lower

Shares optical equipment makers are trading lower in the after-hours after peer Applied Optoelectronics (AAOI) reported Q3 preliminary results that fell short of estimates. The maker of fiber-optic networking products dramatically lowered both its profit and revenue view for the quarter. The company now anticipates Q3 earnings per share of 91c-96c, down from its prior view of $1.30-$1.43. Revenue is expected to be $88M-$89M, lower than prior expectations of $107M-$115M. Analysts were expecting EPS of $1.31 on revenue of $111.58M for Q3. MANAGEMENT COMMENTARY: "Our preliminary results for the third quarter fell short of prior estimates and were negatively impacted by lower than expected sales to one of our large datacenter customers. Despite this shortfall, we maintained a strong gross margin profile in the quarter, and continued to experience solid demand with our other top datacenter customers," said Dr. Thompson Lin, Applied Optoelectronics founder, president, and CEO. "Although we are disappointed with these preliminary results, we continue to feel good about our leadership position in advanced optics and remain optimistic based on the customer traction we are seeing with our 100G products, especially our 100G CWDM transceivers." RECENT ANALYST VIEWS: On October 3, Craig-Hallum analyst Richard Shannon lowered his price target for Applied Optoelectronics to $80 from $95 on 40G transition acceleration and Intel (INTC) competitive threat. Nonetheless, the analyst says 100G+ remains robust, and Applied Optoelectronics' cost structure enables it to compete effectively. He reiterated a Buy rating on Applied Optoelectronics' shares at the time. Just a day before, on October 2, BWS Financial analyst Hamed Khorsand said he believed Applied Optoelectronics sales to Amazon (AMZN) have softened even more as the company moves away from 40G. He also thinks Intel's start of shipments of competing CWDM4 transceivers poses a threat to 100G revenue Applied has been generating from Facebook (FB). Khorsand kept his Sell rating on Applied Optoelectronics shares. PRICE ACTION: Shares of Applied Optoelectronics are down more than 18% to $48.10 per share in after-hours trading. OPTICAL PEERS LOWER: Shares of other companies in the space are all lower in post-market action, with Lumentum (LITE) down 2% to $57.80 per share, Finisar (FNSR) lower by 1.5% to $21.96 per share, and Oclaro (OCLR) falling 2.2% to $8.42 per share.

AAOI

Applied Optoelectronics

$58.84

-2.6 (-4.23%)

FNSR

Finisar

$22.28

0.48 (2.20%)

OCLR

Oclaro

$8.61

0.05 (0.58%)

LITE

Lumentum

$58.95

0.95 (1.64%)

INTC

Intel

$39.19

-0.11 (-0.28%)

AMZN

Amazon.com

$1,000.93

5.93 (0.60%)

FB

Facebook

$172.55

-0.19 (-0.11%)

  • 12

    Oct

  • 12

    Oct

  • 16

    Oct

  • 16

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 26

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 16

    Nov

AAOI Applied Optoelectronics
$58.84

-2.6 (-4.23%)

08/16/17
RAJA
08/16/17
NO CHANGE
RAJA
Strong Buy
Raymond James maintains Strong Buy rating on Applied Optoelectronics
Raymond James analyst Applied Simon Leopold maintained a Strong Buy and $107 price target on Applied Optoelectronics following a recent field trip. The analyst said Applied often gets grouped in with optical component stocks, but its differentiated through its focus on data center applications, scale and automation. Simon recommends investors take the time to listen to the story and further understanding will lead to increased appreciation.
08/24/17
NEED
08/24/17
NO CHANGE
NEED
China Mobile tender offer looks 'significant' for optical stocks, says Needham
Needham analyst Alex Henderson said the coherent transport ports tender offer announced by China Mobile (CHL) on its Chinese language website looks "significant in scale and material" for optical stocks. He noted that NeoPhotonics (NPTN) gets roughly 60% of revenue from China and is directly exposed to coherent demand, while Acacia (ACIA) gets 50% of revenue from China and is also directly exposed. He noted that Oclaro (OCLR), Lumentum (LITE), Finisar (FNSR) all have China exposure, but are less tied to coherent, while adding that "this order has no bearing" on Applied Optoelectronics (AAOI).
10/02/17
BWSF
10/02/17
NO CHANGE
BWSF
Sell
BWS Financial sees Applied Optoelectronics sales to Amazon softening further
BWS Financial analyst Hamed Khorsand said he believes Applied Optoelectronics (AAOI) sales to Amazon (AMZN) have softened even more as the company moves away from 40G. He also thinks Intel's (INTC) start of shipments of a competing CWDM4 transceivers poses a threat to 100G revenue Applied has been generating from Facebook (FB). Khorsand keeps his Sell rating on Applied Optoelectronics shares.
10/03/17
CHLM
10/03/17
NO CHANGE
Target $80
CHLM
Buy
Applied Optoelectronics price target lowered to $80 from $95 at Craig-Hallum
Craig-Hallum analyst Richard Shannon lowered his price target for Applied Optoelectronics (AAOI) to $80 from $95 on 40G transition acceleration and Intel (INTC) competitive threat. Nonetheless, the analyst says 100G+ remains robust, and Applied Optoelectronics' cost structure enables it to compete effectively. He reiterates a Buy rating on Applied Optoelectronics' shares.
FNSR Finisar
$22.28

0.48 (2.20%)

09/08/17
NEED
09/08/17
NO CHANGE
NEED
Finisar price target lowered to $34 from $44 at Needham
Needham analyst Alex Henderson lowered his price target on Finisar after the company cut its Q3 guidance. However, he keeps a Strong Buy rating on the stock.
09/17/17
PIPR
09/17/17
NO CHANGE
Target $26
PIPR
Overweight
Finisar has catalysts to help accelerate growth, says Piper Jaffray
Piper Jaffray analyst Troy Jensen recommends investors revisit Finisar shares as he believes the optical group will likely experience accelerating growth in 2018 and believes Finisar has some company specific catalysts to help accelerate growth. The analyst believes China demand will improve by year-end and into 2018 with inventor levels being reduced and new China tenders helping grow demand. Jensen also believes Finisar will see VCSEL sales start an impressive ramp in October, coupled with initial revenues for the CFP2-ACO qualification at Cisco in the January quarter followed by ROADM line cards in the April quarter. This growth recovery coupled with lowered assumptions and valuation creates an "attractive entry point," he contends. The analyst reiterates an Overweight rating and $26 price target on the shares.
10/06/17
JEFF
10/06/17
NO CHANGE
Target $75
JEFF
Buy
Jefferies boosts Lumentum target to $75 on 3D sensing opportunity
After speaking to contacts and building an industry model, Jefferies analyst James Kisner believes investors may be underestimating the longer-term impact to earnings from 3D sensing, particularly for Lumentum (LITE), given its market leadership. The analyst's base case has the revenue opportunity for lasers and filters for 3D sensing ramping from $31M in 2017 to $1B in 2018 and $3.5B in 2023. Lumentum is the biggest beneficiary of 3D sensing as Finisar (FNSR) is capacity limited and Viavi's (VIAV) filters have relatively low average selling prices, Kisner tells investors in a research note. He raised his estimates for Lumentum while modestly lowering numbers for Finisar and Viavi. The analyst also boosted his price target for Lumentum to $75 from $72. Kisner has Buy ratings on all three names.
09/08/17
MKMP
09/08/17
NO CHANGE
MKMP
Finisar catlysts just 'delayed,' not 'canceled,' says MKM Partners
After Finisar's Q2 guidance came in well below expectations, MKM Partners analyst Michael Genovese says that "all of the meaningful catalysts for the stock are delayed, but none are canceled." He says that "the most important catalyst," 3D Sensing, "is only delayed by one quarter," while two other positive catalysts - "full Verizon qualification and demand recovery in China" - "are delayed by 1-2 quarters." He trimmed his price target on the name to $31 from $33 but keeps a Buy rating on the stock.
OCLR Oclaro
$8.61

0.05 (0.58%)

09/05/17
STFL
09/05/17
NO CHANGE
Target $30
STFL
Buy
Finisar estimates lowered following peer commentary at Stifel
Stifel analyst Patrick Newton has lowered his FY18 and FY19 estimates for Finisar (FNSR) and is now modeling one more step down in China following recent commentary from competitors such as Lumentum (LITE), Oclaro (OCLR) and MACOM (MTSI) indicating that China is expected to decline again sequentially in the September quarter. Based on the reduced expectations, he lowered his price target on Finisar shares to $30 from $33, but he maintains a Buy rating on the stock.
09/14/17
RAJA
09/14/17
INITIATION
Target $12
RAJA
Strong Buy
Oclaro initiated with a Strong Buy at Raymond James
Raymond James initiated Oclaro with a Strong Buy and a $12 price target.
09/15/17
RAJA
09/15/17
INITIATION
Target $12
RAJA
Strong Buy
Oclaro initiated with a Strong Buy, high speed optics leader at Raymond James
Raymond James analyst Simon Leopold initiated Oclaro with a Strong Buy and a $12 price target saying it is a leader in high speed optics primarily for telco and enterprises with expansion in the web scale vertical. The analyst sees meaningful upside to shares, double digit sales growth, and gross margins remaining above historical levels.
09/15/17
09/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Overweight at JPMorgan. 2. Lionsgate (LGF.A) initiated with an Outperform at FBN Securities. 3. Sage Therapeutics (SAGE) initiated on huge potential at RBC Capital. 4. Verifone (PAY) initiated with a Neutral at Citi. 5. Oclaro (OCLR) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
LITE Lumentum
$58.95

0.95 (1.64%)

10/09/17
PIPR
10/09/17
NO CHANGE
Target $68
PIPR
Overweight
Lumentum remains best way to play 3D sensing market, says Piper Jaffray
Piper Jaffray analyst Troy Jensen says Lumentum remains the best way to play the 3D sensing market after recent data points suggested demand continues to surge. Consensus estimates look too conservative for the company's VCSEL business, Jensen tells investors in a research note. He reiterates an Overweight rating on Lumentum with a $68 price target.
10/04/17
RSBL
10/04/17
NO CHANGE
RSBL
Lumentum mentioned positively at Rosenblatt
09/27/17
09/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Darden (DRI) was upgraded to Buy from Hold at Maxim and to Outperform from Neutral at Baird. 2. Michael Kors (KORS) upgraded to Buy from Hold at Canaccord with analyst Camilo Lyon saying he believes the strategic steps management has recently begun implementing are showing signs of traction. 3. RBS (RBS) upgraded to Buy from Hold at Jefferies. 4. Lumentum (LITE) upgraded to Buy from Neutral at MKM Partners with analyst Michael Genovese citing valuation and his checks which lead him to believe that orders for the 3D Sensing product "rose significantly"since it reported its results on August 9. 5. Telefonica (TEF) upgraded to Buy from Hold at Berenberg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
INTC Intel
$39.19

-0.11 (-0.28%)

10/04/17
JEFF
10/04/17
NO CHANGE
Target $5
JEFF
Buy
Jefferies says Intelsat C-band proposal a 'welcome, but speculative' development
After news that Intelsat (I) and Intel (INTC) have submitted a proposal to share a portion of the C-band with mobile operators, Jefferies analyst Giles Thorne said that while it was not made explicit he would assume that Intelsat wants to lease access to its spectrum. The analyst, who called this news "a welcome, but speculative, development," said it is challenging to estimate the size of a potential revenue stream, adding that if the FCC were to approve the plan "there won't be a 'quid' without a 'quo'." Thorne keeps a Buy rating and $5 price target on Intelsat shares, which gained about 11% yesterday to close at $5.37.
10/06/17
MKMP
10/06/17
NO CHANGE
Target $78
MKMP
Neutral
Xilinx price target raised to $78 from $63 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Xilinx (XLNX) to $78 from $63, noting that recent conversations with the company indicate healthy demand trends. The analyst added that the feedback related to the Industrial and Aerospace/Defense markets was especially positive, even as communications infrastructure space will remain mixed for the rest of FY17. Competitive dynamics will also remain favorable, with Intel (INTC) unlikely to gain any meaningful market share, added Roy, who kept his Neutral rating on Xilinx shares.
AMZN Amazon.com
$1,000.93

5.93 (0.60%)

10/12/17
OPCO
10/12/17
NO CHANGE
OPCO
Outperform
Oppenheimer sees Amazon retargeting solution as emerging opportunity for Kenshoo
Oppenheimer analyst Jason Helfstein noted he hosted a conference call with Oren Stern, General Manager of eCommerce Solutions at Kenshoo, a digital marketing platform, to discuss Amazon's e-Commerce product. The analyst says Stern believes that advertising budgets on Amazon are incremental to other digital formats such as search and social, and should hasten the shift from offline to online advertising. While Stern would not comment on Amazon's re-targeting solution - off platform on other websites - using its 1P data, Helfstein points out that he sees it as an emerging opportunity for the company. The analyst has an Outperform rating on Amazon's shares.
10/11/17
FBCO
10/11/17
NO CHANGE
Target $1350
FBCO
Outperform
Amazon.com price target raised to $1350 from $1100 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Amazon to $1350 from $1100 ahead of Q3 results. The analyst believes the combination of Prime Now with Whole Foods presents what he had originally thought would be the rollout of Amazon Fresh in late-2013/early-2014, and sees Amazon over the medium term expanding Prime Now's presence by up to 50%. While price cuts capture the headlines, Ju submits that Amazon will wage war with its competitors with service instead. He reiterates an Outperform rating on the shares.
10/10/17
MAXM
10/10/17
NO CHANGE
Target $78
MAXM
Buy
Express Scripts risks balanced from Amazon entry into drug business, says Maxim
Maxim analyst Anthony Vendetti says that if Amazon (AMZN) decides to enter into the prescription drug business as its own pharmacy benefit manager, it would represent a long-term threat to Express Scripts (ESRX). However, Vendetti contends that Amazon would be better served to partner with an existing industry player or acquire one and believes that Express Scripts would be an attractive choice in either scenario. The analyst, who has already modeled a potential loss of the Anthem business in FY20 and beyond, maintains a Buy rating and a $78 price target on Express Scripts.
10/10/17
LEHM
10/10/17
NO CHANGE
Target $1150
LEHM
Overweight
Amazon.com quarter could be 'another mixed-bag,' says Barclays
Barclays analyst Ross Sandler thinks Amazon.com's Q3 may be "another mixed-bag" like last quarter, with revenue and operating income ahead of consensus, but Q4 guidance disappointing on operating income. The company's retail profitability is likely to continue to suffer near term from heavy investments in both core Amazon and Whole Foods, Sandler tells investors in a pre-earnings research note. He believes, however, that most investors understand that margin is available when Amazon decides to capture more. He does not see a "ton of downside" in the stock, saying revenue growth is "what matters most at this stage of development." The analyst recommends using on share pullback on profitability concerns as a buying opportunity. Amazon remains Sandler's longer term top pick in the Internet & Media space. He has an Overweight rating on the shares with a $1,150 price target.
FB Facebook
$172.55

-0.19 (-0.11%)

10/11/17
FBCO
10/11/17
NO CHANGE
Target $235
FBCO
Outperform
Facebook price target raised to $235 from $190 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Facebook to $235 from $190 ahead of Q3 results as he increases his mobile newsfeed estimates on the heels of positive advertiser checks. The analyst reiterates an Outperform rating on the shares.
10/11/17
PIPR
10/11/17
NO CHANGE
PIPR
Overweight
Piper teen survey shows 'clear challenges' for Facebook and Twitter
Piper Jaffray analyst Sam Kemp says his firm's bi-annual survey of over 6,000 teens shows "clear challenges" for both Facebook (FB) and Twitter (TWTR). The youngest of teens "are simply not adopting these platforms," Kemp tells investors in a research note. The survey indicated 82% and 81% of teens are using Snapchat (SNAP) and Facebook's Instagram, respectively, and that these platforms share 93% of their users with each other. Kemp believes this is positive for Instagram as it's "ad unit and advertiser adoption are well ahead of Snap." Instagram is faring well against Snapchat, the analyst contends. He points out that his firm's longitudinal cohort data shows engagement is not declining with older cohorts on Facebook. Kemp reiterates an Overweight rating on Facebook and a Neutral rating on Snap.
10/05/17
NEED
10/05/17
NO CHANGE
NEED
Checks on Facebook positive, says Needham
After conducting checks, Needham analyst Laura Martin says that the company "is hitting on all cylinders," with Instagram and Messenger causing her to raise her ad supply and targeting estimates for the company. Martin adds that the company's user growth is exceeding her prior expectations. The analyst raised her estimates for the company and keeps a $185 price target and a Buy rating on the shares.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.